Paratek Pharmaceuticals, Boston-based biopharmaceutical company, announced that the U.S. FDA has granted omadacycline Fast Track Designation for the development of omadacycline in Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community Acquired Bacterial Pneumonia (CABP), and Complicated Urinary Tract Infections (cUTI).  Omadacycline, the first in a new class of tetracyclines known as aminomethylcyclines, is being developed as a once-daily oral and IV therapy to treat serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern.  Each year in the United States, at least 2 million people are infected with bacteria that are resistant to existing antibiotics; at least 23,000 people die each year as a direct result of these infections.